Oramed Pharmaceuticals Inc. — Director's Dealing 2021

Aug 6, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2021-08-04

Reporting Person: Rabinowitz Michael (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-04	Common Stock	A	100000	—	Acquired	100000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-04	Stock Option (right to buy)	$15.10	A	100000	Acquired	2031-08-04	Common Stock (100000)	Direct

Footnotes

F1: Represents common stock underlying Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F2: The RSUs will vest as follows: 33,333 shall vest if the closing price per share of the Issuer's common stock will be $15 for at least 20 days, 33,333 shall vest if the closing price per share of the Issuer's common stock will be $25 for at least 20 days, and 33,334 shall vest if the Issuer consummates an arm's length licensing or other strategic transaction, that includes its phase 3 oral insulin product, for no less than $50,000,000 in upfront cash (including proceeds from any upfront stock equity purchase).

F3: The Stock Options will vest in five installments as follows: 12,500 shall vest on December 31, 2021, 25,000 shall vest on each of December 31, 2022, December 31, 2023 and December 31, 2024, and 12,500 shall vest on August 4, 2025.